Inactive Instrument

Highlights Aytu Bioscience Inc Nasdaq

Equities

US0547544033

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

Earnings Flash (AYTU) AYTU BIOPHARMA Reports Q3 Revenue $18M, vs. Street Est of $17.4M	May. 15	MT
Earnings Flash (AYTU) AYTU BIOPHARMA Reports Q2 Revenue $22.9M, vs. Street Est of $21.75M	Feb. 14	MT
Aytu BioPharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023	Feb. 14	CI
Earnings Flash (AYTU) AYTU BIOPHARMA Posts Q1 Revenue $22.1M, vs. Street Est of $27.7M	Nov. 14	MT
Aytu BioPharma, Inc. Reports Earnings Results for the First Quarter Ended September 30, 2023	Nov. 14	CI
Aytu BioPharma Gets FDA Approval to Transfer Production of Cotempla to Third Party	23-10-26	MT
Aytu BioPharma, Inc. Announces Approval of the Cotempla XR-ODT Manufacturing Site Transfer Prior Approval Supplement	23-10-26	CI
Earnings Flash (AYTU) AYTU BIOPHARMA Posts Q4 Revenue $30.7M, vs. Street Est of $27.7M	23-09-27	MT
Aytu BioPharma, Inc. Reports Earnings Results for the Fourth Quarter Ended June 30, 2023	23-09-27	CI
Aytu BioPharma, Inc. Reports Earnings Results for the Full Year Ended June 30, 2023	23-09-27	CI
Aytu BioPharma, Inc. Announces Exclusive Agreement with Medomie Pharma Ltd. to Commercialize Adzenys XR-ODT(R) and Cotempla XR-OT(R) in Israel and the Arab Authority	23-07-31	CI
Aytu BioPharma, Inc. Announces Submission of Cotempla XR-ODT(R) Manufacturing Site Transfer Prior Approval Supplement	23-07-10	CI
Aytu BioPharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2023	23-05-11	CI
Aytu BioPharma Subleases A Portion of Its Manufacturing Facility	23-05-01	CI
Aytu Biopharma, Inc. Announces Successfully Completion of Cotempla XR-ODT Bioequivalence Study	23-04-27	CI
Aytu BioPharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2022	23-02-21	CI
Earnings Flash (AYTU) AYTU BIOPHARMA Posts Q2 Revenue $26.3M	23-02-21	MT
Aytu Biopharma, Inc. Continues Availability of Adzenys XR-ODT(R) as the Only FDA-Approved Orally Disintegrating Tablet Medication That Is Bioequivalent to Adderall XR(R) for Adhd Patients	23-01-10	CI
Earnings Flash (AYTU) AYTU BIOPHARMA Posts Q1 Revenue $27.7M, vs. Street Est of $24.3M	22-11-14	MT
Aytu BioPharma, Inc. Reports Earnings Results for the First Quarter Ended September 30, 2022	22-11-14	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Aytu Bioscience Inc Nasdaq

Equities

US0547544033

Highlights

Filters